Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516374 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

Complement and CD14: Roles in Escherichia coli-induced inflammation. Edition No. 1

VDM Publishing House, June 2010, Pages: 124


  Description  
   Authors   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Sepsis is a systemic inflammatory response syndrome caused by infection. A range of biomarkers have been shown to correlate with disease activity and death in sepsis. However, targeting single downstream mediators in clinical sepsis trials, like the central proinflammatory cytokine TNF-?, have been disappointing. A better approach may be inhibition of upstream inducers instead of downstream mediators of inflammation. The aims of this study were to find effective inhibitors of complement and CD14/TLR4/MD2, two key upstream innate immunity inducers of inflammation The studies were conducted in vitro and in vivo in a pig model. The pig is a well suited animal for studying human diseases. The anatomy and physiology is quite similar to humans, and pigs are LPS sensitive in contrast to rodents. Upstream inhibition of both complement and CD14/TLR4/MD2 were found to be effective in reduction of E. coli-induced inflammation. Induction of central proinflammatory cytokines, activation of hemostasis, and activation of granulocytes, by E. coli, were reduced. The findings suggest that inhibition of complement and CD14/TLR4/MD2 should be regarded as an early treatment approach in sepsis.



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds